Skip to content

Autograft of Human Ovarian Tissue : Efficiency and Safety

Autograft of Human Ovarian Tissue: Efficiency and Safety Evaluation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02184806
Acronym
CAROLéLISA
Enrollment
40
Registered
2014-07-09
Start date
2010-06-30
Completion date
2019-01-31
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Tissue Transplantation

Keywords

Ovarian tissue transplantation, Cryopreserved ovarian tissue

Brief summary

Ovarian tissue cryopreservation is a new technique for female fertility preservation. One way to restore fertility is autotransplantation of ovarian tissue. The principal purpose of this study will be to evaluate the efficiency and safety of this procedure.

Detailed description

Ovarian tissue cryopreservation is a new technique for female fertility preservation before gonadotoxic treatments. The first ovarian tissue cryopreservations were performed 10 years ago. There are two main methods to use frozen ovarian cortex: autograft of ovarian fragments and in vitro follicular growth. At the present time, none mature oocytes were obtained after culture. Since 2000, around twenty publications stating autografts of ovarian cortex reported 8 pregnancy and 6 life birth of healthy babies. Since 1998 until 2008, in the unit of reproduction biology of pitie-salpetriere hospital in Paris, France, 330 patients have had an ovarian tissue cryopreservation for fertility preservation before gonadotoxic treatment. Among them, at the present time, 180 have a procreative age and in consequence, could ask for the use of their ovarian cortex. The general aim of this protocol will be to propose to women wishing to have a baby, an ovarian tissue transplantation if the patients have an premature ovarian failure. The principal aim of this study will be to evaluate the efficiency and the safety of ovarian transplantation. Before grafting, the absence of contra- indication will be check. An informed consent will be signed by the patient. Autograft of ovarian cortex will be performed either in orthotopic or in heterotopic localization according to the pathology and a possible contra-indication to orthotopic position. After graft, each month hormonal assessment, ovarian echography and, after 3 months, an MRI, will be performed. Assisted Reproductive Technologies (ART) will be performed in case of heterotopic graft and if necessary in case of orthotopic graft. The efficiency of ovarian tissue autograft will be appreciated by the delay before the recovery of the ovarian function, the oocyte and embryos qualities in case of ART. Finally, the number of pregnancies and live births will be also appreciated as well as a possible recurrence of the pathology.

Interventions

PROCEDUREorthotopic graft

(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or

PROCEDUREheterotopic graft

1. put under the skin 2. the ovarian fragments can be put under the skin of the abdomen

Sponsors

Agence de La Biomédecine
CollaboratorOTHER_GOV
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

: * adult women (age ≥ 18 years old) who stored ovarian fragments before gonadotoxic treatments * Women who desire to conceive * Married women or in stable couple * Cured women or in remission * Women suffering of Premature ovarian failure * Consenting women * women with health insurance

Exclusion criteria

: * age \< 18 years * women with normal ovarian function * women with a disease at high risk for ovarian metastasis * women with contraindication for surgery * women with contraindication for pregnancy * not cured women or not in remission * women without health insurance

Design outcomes

Primary

MeasureTime frameDescription
Biological (FSH, LH, E2 and AMH) changes from graft until the revovery of ovarian functionevery month after graft, up to 18 monthsFSH, LH, E2 and AMH follow up every month after graft until the recovery of ovarian function, up to 18 months
Radiological (ultrasonography and MRI) changes in ovarian imaging from graft until the revovery of ovarian functionevery month after graft, up to 18 monthsRadiological (only ultrasonography the first 3 months and after ultrasonography and MRI) follow up every month after graft until the recovery of ovarian function, up to 18 months

Secondary

MeasureTime frame
Graft vascularizationevery month up to 18 months
Relapse of the pathologyevery month up to 18 months
Delay and quality of the ovarian function recovery between ortho and heterotopic graftafter ovarian function recovery, up to 18 months
Number of ovarian fragments necessary for ovarian function recoveryup to 18 months

Countries

France

Contacts

Primary ContactPoirot Catherine, MD, PhD
Catherine.poirot@tnn.aphp.fr+33 1 56 01 78 00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026